[Prevention of venous thromboembolic events by fondaparinux 2.5mg in patients hospitalized for an acute medical illness. ArchiMed Study]

Autor: C, Leroyer, I, Mahé, J-P, Daurès, I, Quéré, C, Aubin, A, Compagnon, J, Doussaint, S, Schück, D, Pouchain
Přispěvatelé: Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Recherche Clinique ville-hôpital, Méthodologies et Société (REMES), Université Paris Diderot - Paris 7 (UPD7), Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Caractéristiques féminines des dysfonctions des interfaces cardio-vasculaires (EA 2992), Laboratoire GlaxoSmithKline [ Marly-le-Roi], Kappa, Université Francois Rabelais [Tours]
Jazyk: francouzština
Rok vydání: 2015
Předmět:
Zdroj: Journal des Maladies Vasculaires
Journal des Maladies Vasculaires, Elsevier Masson, 2015, 40 (4), pp.248-258. ⟨10.1016/j.jmv.2015.05.001⟩
ISSN: 0398-0499
DOI: 10.1016/j.jmv.2015.05.001⟩
Popis: International audience; OBJECTIVE:To evaluate the average duration of in-hospital treatment with fondaparinux 2.5mg prescribed for venous thromboprophylaxis in acutely ill medical patients and to describe the treatment population.METHODS:Prospective, observational, national, multicentre, epidemiological study, performed in France at the request of the Transparency Commission of the French National Health Authority (Haute Autorité de Santé). This is part of a larger study program that also included a study with similar design in the general practice setting. The hospital practice part of the study was conducted by hospital pharmacists who were asked to include the first 15 adult subjects hospitalized in a non-surgical ward for whom fondaparinux 2.5mg was initiated for prophylaxis.RESULTS:Fifty-three pharmacists (49.5%) included a total of 718 patients. The average age was 71 ± 16 years (47%
Databáze: OpenAIRE